| HOME >> MEDICINE >> TECHNOLOGY |
194,668
27.6%Cost of revenues:Laboratory Services(59,255)
(44,546)
33.0%(113,742)
(87,258)
30.4%Manufacturing Services(24,631)
(17,938)
37.3%(46,281)
(34,086)
35.8%Total cost of revenues(83,886)
(62,484)
34.3%(160,023)
(121,344)
31.9%Gross profit:Laboratory Services34,289
30,480
12.5%66,452
58,076
14.4%Manufacturing Services12,206
8,149
49.8%21,934
15,248
43.8%Total gross profit46,495
38,629
20.4%88,386
73,324
20.5%Operating expenses:Selling and marketing expenses(3,729)
(2,547)
46.4%(7,007)
(4,505)
55.5%General and administrative expenses(16,911)
(13,608)
24.3%(33,073)
(25,782)
28.3%Research and development expenses(2,080)
(961)
116.4%(3,893)
(1,684)
131.2%Total operating expenses(22,720)
(17,116)
32.7%(43,973)
(31,971)
37.5%Operating income23,775
21,513
10.5%44,413
41,353
7.4%Other income (expenses), net:Other income (expenses), net(580)
149
(489.3%)2,160
1,776
21.6%Interest income (expenses), net1,425
975
46.2%3,124
1,806
73.0%Total other income (expenses), net845
1,124
(24.8%)5,284
3,582
47.5%Income before income taxes24,620
22,637
8.8%49,697
44,935
10.6%Income tax expense(4,128)
(3,986)
3.6%(8,216)
(8,060)
1.9%Net income20,492
18,651
9.9%41,481
36,875
12.5%Basic net earnings per ADS0.29
0.26
8.6%0.58
0.52
10.5%Diluted net earnings per ADS0.28
0.25
13.4%0.56
0.49
14.9%We
'/>"/>
| SOURCE WuXi PharmaTech (Cayman) Inc. Copyright©2012 PR Newswire. All rights reserved |